These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29775170)

  • 21. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
    Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
    Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery of dabigatran etexilate for the treatment of venous thrombosis.
    Feuring M; van Ryn J
    Expert Opin Drug Discov; 2016 Jul; 11(7):717-31. PubMed ID: 27159158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER
    Feuring M; Schulman S; Eriksson H; Kakkar AJ; Schellong S; Hantel S; Schueler E; Kreuzer J; Goldhaber SZ
    J Thromb Thrombolysis; 2017 May; 43(4):484-489. PubMed ID: 28210989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral venous congestion as indication for thrombolytic treatment.
    Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
    Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Goldhaber SZ; Schellong S; Kakkar A; Eriksson H; Feuring M; Kreuzer J; Fraessdorf M; Schulman S
    Thromb Haemost; 2016 Sep; 116(4):714-21. PubMed ID: 27411591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
    Klok FA; Toenges G; Mavromanoli AC; Barco S; Ageno W; Bouvaist H; Brodmann M; Cuccia C; Couturaud F; Dellas C; Dimopoulos K; Duerschmied D; Empen K; Faggiano P; Ferrari E; Galiè N; Galvani M; Ghuysen A; Giannakoulas G; Huisman MV; Jiménez D; Kozak M; Lang IM; Lankeit M; Meneveau N; Münzel T; Palazzini M; Petris AO; Piovaccari G; Salvi A; Schellong S; Schmidt KH; Verschuren F; Schmidtmann I; Meyer G; Konstantinides SV;
    Lancet Haematol; 2021 Sep; 8(9):e627-e636. PubMed ID: 34363769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis.
    Yaghi S; Saldanha IJ; Misquith C; Zaidat B; Shah A; Joudi K; Persaud B; Abdul Khalek F; Shu L; de Havenon A; Mistry EA; Bakradze E; Goldstein ED; Reagan J; Theodorou A; Palaiodimou L; Furie K; Field TS; Tsivgoulis G; Mac Grory B
    Stroke; 2022 Oct; 53(10):3014-3024. PubMed ID: 35938419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
    Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
    Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
    Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
    BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 34. Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy.
    Wilbur J; Shian B
    Am Fam Physician; 2017 Mar; 95(5):295-302. PubMed ID: 28290648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
    BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial.
    Coutinho JM; Ferro JM; Zuurbier SM; Mink MS; Canhão P; Crassard I; Majoie CB; Reekers JA; Houdart E; de Haan RJ; Bousser MG; Stam J
    Int J Stroke; 2013 Feb; 8(2):135-40. PubMed ID: 22340437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.